Ulcerative Colitis – Access & Reimbursement – Detailed, Expanded Analysis (EU5)

MARKET OUTLOOK

The ulcerative colitis (UC) market landscape is constantly evolving. The TNF-α inhibitors have the longest tenure among all biologics for UC; however, the launch of Takeda’s Entyvio, a cell adhesion molecule (CAM) inhibitor, intensifies competition. The additional entries and expanded use of less-expensive biosimilar TNF-α inhibitors will also continue to shift market dynamics, as will the anticipated entry of the first-in-UC oral therapy (i.e., Pfizer’s Xeljanz), together with the launch of additional emerging agents with novel MOAs. All these factors will contribute to an increasingly complex market access landscape. EU5 payers and prescribers will need to carefully weigh the clinical efficacy, safety, and cost-effectiveness of each agent. As such, developers of emerging therapies looking to penetrate this market need to be wellprepared to navigate a more-complex road to access and reimbursement.

QUESTIONS ANSWERED

  • What clinical and cost-related factors most strongly influence and restrict prescribing of key UC therapies? How do these differ across the EU5?
  • What factors will determine the success of recently approved and emerging agents, including Xeljanz? How do payers intend to reimburse emerging agents? To what extent will payer policy impact prescribing of them?
  • What can manufacturers do to achieve favorable pricing and reimbursement terms, maximize uptake, and therefore optimize market access?

PRODUCT DESCRIPTION

Access & Reimbursement provides in-depth insight regarding the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.

GEOGRAPHY

EU5: France, Germany, Italy, Spain, United Kingdom

PRIMARY RESEARCH

Survey of 250 gastroenterologists across the EU5 (50 per country)

Interviews with 10 EU5 payers (2 per country)

KEY DRUGS COVERED

Humira, Remicade, Simponi, Entyvio, Stelara, Inflectra/Remsima/Flixabi, Xeljanz, ozanimod, etrolizumab

CONTENT HIGHLIGHTS

  • Actionable recommendations to optimize market access
  • Market access success and stumbles
  • Market access roadblocks
  • Reimbursement dynamics
  • The impact of pricing and reimbursement, policy, and coverage on prescribing
  • Market access outlook for emerging therapies

Table of contents

  • Ulcerative Colitis - Access & Reimbursement - Detailed, Expanded Analysis (EU5)
    • Ulcerative Colitis - Access & Reimbursement - EU5